About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
UCB Inc. et al. v. Aurobindo Pharma Ltd., et al.
1:13-cv-01210; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.
UCB Inc. et al. v. Accord Healthcare Inc. et al.
1:13-cv-01206; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Accord Healthcare Inc.; Intas Pharmaceuticals Ltd.
UCB Inc. et al. v. Alembic Pharmaceuticals Ltd. et al.
1:13-cv-01207; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Alembic Pharmaceuticals Ltd.; Alembic Ltd.; Alembic Pharma Ltd.
UCB Inc. et al. v. Amneal Pharmaceuticals LLC et al.
1:13-cv-01208; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York LLC; Amneal Pharmaceuticals Co. India Private Ltd.
UCB Inc. et al. v. Apotex Corp. et al.
1:13-cv-01209; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Apotex Corp.; Apotex Inc.
UCB Inc. et al. v. Breckenridge Pharmaceutical Inc. et al.
1:13-cv-01211; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Breckenridge Pharmaceutical Inc.; Vennoot Pharmaceuticals LLC
UCB Inc. et al. v. Glenmark Generics Inc. USA et al.
1:13-cv-01212; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Glenmark Generics Inc. USA; Glenmark Generics Ltd.
UCB Inc. et al. v. Hetero USA Inc. et al.
1:13-cv-01213; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Hetero USA Inc.; Hetero Labs Limited Unit V
UCB Inc. et al. v. Mylan Pharmaceuticals Inc. et al.
1:13-cv-01214; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
UCB Inc. et al. v. Ranbaxy Laboratories Ltd. et al.
1:13-cv-01215; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Ranbaxy Laboratories Ltd.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy Inc.
UCB Inc. et al. v. Sandoz Inc.
1:13-cv-01216; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendant: Sandoz Inc.
UCB Inc. et al. v ScieGen Pharmaceuticals Inc. et al.
1:13-cv-01217; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: ScieGen Pharmaceuticals Inc.; Bactolac Pharmaceutical Inc.
UCB Inc. et al. v Sun Pharma Global FZE et al.
1:13-cv-01218; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Inc.
UCB Inc. et al. v. Watson Laboratories Inc. - Florida et al.
1:13-cv-01219; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Watson Laboratories Inc. – Florida; Watson Pharma Inc.; Actavis Inc.
UCB Inc. et al. v. Zydus Pharmaceuticals (USA) Inc. et al.
1:13-cv-01220; filed July 10, 2013 in the District Court of Delaware
• Plaintiffs: UCB Inc.; UCB Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants: Zydus Pharmaceuticals (USA) Inc.; Cadila Healthcare Ltd.
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. RE38,551 ("Anticonvulsant Enantiomeric Amino Acid Derivatives," issued July 6, 2004) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of UCB's Vimpat® (lacosamide, used as adjunctive therapy in the treatment of partial-onset seizures in people with epilepsy aged 17 years and older). View the Aurobindo complaint here.
Par Pharmaceutical, Inc. et al. v. Takeda Pharmaceutical Co., Ltd. et al.
3:13-cv-03151; filed July 9, 2013 in the Northern District of California
• Plaintiffs: Par Pharmaceutical, Inc.; Handa Pharmaceuticals, LLC
• Defendants: Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceuticals America, Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Declaratory judgment of invalidity and/or non-infringement of U.S. Patent No. 8,461,187 ("Multiple PPI Dosage Form," issued June 11, 2013) in conjunction with Par's filing of an ANDA to manufacture a generic version of Takeda's Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive esophagitis, maintaining healing of esophagitis, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease). View the complaint here.
University of Utah Research Foundation et al. v. Ambry Genetics
2:13-cv-00640; filed July 9, 2013 in the District Court of Utah
• Plaintiffs: University of Utah Research Foundation; Trustees of the University of Pennsylvania; HSC Research and Development Limited Partnership; Endorecherche; Myriad Genetics
• Defendant: Ambry Genetics
Infringement of U.S. Patent Nos. 5,709,999 ("Linked breast and ovarian cancer susceptibility gene," issued January 20, 1998), 5,747,282 ("17Q-linked breast and ovarian cancer susceptibility gene," issued May 5, 1998), 5,753,441 ("170-linked breast and ovarian cancer susceptibility gene," issued May 19, 1998), 5,837,492 ("Chromosome 13-linked breast cancer susceptibility gene," issued November 17, 1998), 6,033,857 (same title, issued March 7, 2000), 5,654,155 ("Consensus sequence of the human BRCA1 gene," issued August 5, 1997), 5,750,400 ("Coding sequences of the human BRCA1 gene," issued May 12, 1998), 6,051,379 ("Cancer susceptibility mutations of BRCA2," issued April 18, 2000), 6,951,721 ("Method for determining the haplotype of a human BRCA1 gene," issued October 5, 2005), and 7,250,497 ("Large deletions in human BRCA1 gene and use thereof," issued July 31, 2007) based on Ambry's offer of laboratory services, including clinical diagnostic and genomic services, including testing and analysis of BRCA1 and BRCA2 genes. View the complaint here.